Abstract
At Abbott Laboratories' annual meeting in April last year executive v.p. Paul Gerden told stockholders that in the first quarter domestic pharmaceutical results were adversely affected by a lower incidence of acute upper-respiratory infections There are those who would have trouble saying something like that with a straight face, but nobody can accuse Mr. Gerden of glossing over the direct link between profit and illness, the issue that lies at the heart of the dilemma in which the embattled drug industry finds itself today. The main event—or main events have been going on in Washington, stimulated by the Federal Government's growing involvement in the public health. The debate has little to do directly with the current quality of health care as it is affected by ethical (prescription) drugs—those promoted only to the health professions. The quality of ethical drugs inevitably comes into the argument, but the immediate issue is profit, some of it psychic, a ...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
